Two factors ? a genetic mutation and the excessive production of a key enzyme ? have caused some patients with very advanced leukemia to develop resistance to the new anti-cancer drug Gleevec, scientists said on Thursday.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.